Tuberculosis spondylodiscitis in a patient with psoriatic arthritis on targeted synthetic disease-modifying antirheumatic drugs – case report

has been recognised as an important opportunistic infection that occurs in patients with inflammatory rheumatic diseases. The results of global registries show that the risk of reactivation of latent Tb or the development of new Tb infection increases in patients treated with tumour necrosis factor inhibitors (Tnfis). However, the results of randomised clinical studies and few data from everyday practice show that targeted synthetic disease-modifying anti-rheumatic drugs (tsdmards) such as apremilast and janus kinase inhibitors (jaki), have a lower risk of Tb activation compared to Tnfis.